POV: Pharmacist
“Nulla feugiat ipsum arcu mi penatibus fringilla cursus ut mi. At eget condimentum pellentesque in amet.”
The Pharmacist's View >
Intro text here.Intro text here.Intro text here.Intro text here.Intro text here.Intro text here.Intro text here.Intro text here.Intro text here.Intro text here.Intro text here.Intro text here.Intro text here.Intro text here.Intro text here.Intro text here.Intro text here.Intro text here.
The Pharmacist's View >
The Nurse's View >
January 6, 2025
Comprehensive write-up of the most impactful articles from our monthly Literature Update. December 2024 issue covers Limitations of a Platelet...
December 31, 2024
3-minute video explaining use and implantation of device, Abbott Cardiovascular, 2023
December 31, 2024
Summary of available antiplatelet medication from the Texas Heart Institute; option to view information in Spanish
December 31, 2024
Review of the risks and benefits of aspirin therapy from the Mayo Clinic
December 9, 2024
From Henry Ford Health Anticoag Service - 235-page training manual contains education and training tools along with treatment protocols, diagrams,...
December 5, 2024
December 4, 2024
For patients with acute ischemic stroke and a large vessel occlusion in the proximal anterior circulation who can be treated within 6 hours of stroke...
December 4, 2024
The network meta-analysis of four antithrombotic strategies, demonstrated that in patients with AF undergoing PCI the combination of DAT-based NOAC...
December 4, 2024
In patients with ACS with successful PCI, clopidogrel monotherapy after 1 to 2 months of DAPT failed to attest noninferiority to standard 12 months...
Clinical FAQs provide practical guidance for healthcare professionals through offering evidence-based answers to common questions. These FAQs cover a wide range of topics to help healthcare professionals deliver high-quality patient care.
Are DOACs safe to use in those with low body weight (60 kg)? Should doses be reduced outside of package insert recommendations?
Read MoreWhat is the clinical relevance of a potential interaction between dexamethasone and DOACs (specifically rivaroxaban and apixaban) in general and in...
Read MoreIn patients on long-term oral anticoagulation with stable CAD, is antiplatelet therapy (APT) also indicated?
Read MoreJoining the AC Forum is quick, easy, and free—simply complete our online registration form, and you'll instantly access all membership benefits, including newsletters and webinar invitations. By becoming a member, you join a community of excellence dedicated to improving patient care and advancing the management of thromboembolic diseases. Take the next step in your professional journey and register now to start enjoying the benefits of membership today.
"The knowledge I gained from AC Forum has been invaluable in tackling complex patient cases. While I had a solid foundation, the resources and insights provided by AC Forum helped me expand my expertise significantly."
"The AC Forum Resource Center is a goldmine of information. The resources are incredibly helpful and directly applicable to my daily practice. I frequently turn to the AC Forum website for guidance and support."
"The AC Forum webinars offer invaluable insights into treatment options and the decision-making process behind them. Each patient is unique, and weighing the benefits and risks can be challenging. "